Merck says 'goodbye, Fosamax,' launches authorized generic
Merck put Fosamax and its $3 billion in total 2007 sales in its rear-view mirror yesterday, following the lapse of patent protection on the osteoporosis drug.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.